ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Firm To Collaborate With R. W. Johnson On Vaccines.

December 1, 2000

Senate Subcommittee Adds $98 Million to NCI’s FY 1984 Budget, Assuring Substantial Increase

September 30, 1983

Obituaries: Eleanor Nealson, 59, NCI Liaison to Patients, Formed consumer Advisory Group

October 29, 1999

In Brief: Maguire Wants Five Environmental Experts In Addition To Those On The Board

February 16, 1979

FY2000 Appropriations: NIH Gets $17.9 Billion, A 15% Increase, In Final Budget Agreement; $3 billion to Be Delayed

November 26, 1999

Sanofi Responds to Criticism From Oncologists

November 8, 2012